En Carta Diagnostics raised €5 million in private financing, including €3 million in equity investments and €2 million in nondilutive funding from Bpifrance and others. The funding is aimed at advancing regulatory clearances in the U.S. and Europe for En Carta’s aptamer-based, loop-mediated isothermal amplification testing platform. The company previously received FDA breakthrough device designation for its EC Pocket Lyme point-of-care test and later entered a codevelopment and commercialization agreement for a molecular sexually transmitted infection test with AAZ. En Carta said it will use the new capital to ramp manufacturing with partner Circum Medical and drive commercialization for its Lyme test and future products. For diagnostics companies, the combination of breakthrough designation and added regulatory funding supports a faster push from validation to market authorization, particularly in point-of-care settings where manufacturing scale and documentation are often limiting factors.